MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
Magenta Therapeutics Operating Income 2011-2026 | MGTA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Magenta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -178 M | -102 M | -48.2 M | -29.7 M | -74.7 M | -78.7 M | -83 M | -60 M | -35.7 M | -9.27 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.27 M | -178 M | -69.9 M |
Quarterly Operating Income Magenta Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -40.3 M | -34.9 M | - | -29.9 M | -22.2 M | -17.8 M | - | -15.8 M | -11.8 M | -7.68 M | - | -8.25 M | -18.1 M | -23.8 M | - | -18.2 M | -17.6 M | -18.7 M | - | -18.4 M | -20 M | -21.2 M | -24.6 M | -22.6 M | -19.3 M | -16.4 M | -17.9 M | -16.7 M | -14 M | -11.3 M | -8.17 M | -7.02 M | -15.7 M | -4.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.81 M | -40.3 M | -18 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
-172 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Codiak BioSciences
CDAK
|
-69.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Celsion Corporation
CLSN
|
-14.7 M | - | -6.63 % | $ 13.9 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Chimerix
CMRX
|
-93.1 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.88 | 2.11 % | $ 261 B | Britain |